Table 2.
Study outcomes
| COPS | COLCOT | |||
|---|---|---|---|---|
| Colchicine, N = 396 | Placebo, N = 399 | Colchicine, N = 2366 | Placebo, N = 2379 | |
| Equalized primary composite endpoint: Cardiovascular mortality, resuscitated arrest, myocardial infarction, ischemic stroke, urgent revascularization | ||||
| Events, N (%) | 21 (5.3%) | 40 (10.0%) | 126 (5.3%) | 164 (6.9%) |
| Combined events, N (%) | Colchicine 152 (5.5%) | Placebo 210 (7.6%) | ||
| Summary OR (95% CI) | 0.67 (0.46–0.98) | |||
| Cardiovascular death | ||||
| Events, N (%) | 4 (1.0%) | 2 (0.5%) | 20 (0.8%) | 24 (1.0%) |
| Combined events, N (%) | Colchicine 24 (0.9%) | Placebo 26 (0.9%) | ||
| Summary OR (95% CI) | 0.92 (0.52–1.62) | |||
| Resuscitated cardiac arrest | ||||
| Events, N (%) | 2 (2.3%) | 2 (1.0%) | 5 (1.6%) | 6 (1.8%) |
| Combined events, N (%) | Colchicine 7 (0.25%) | Placebo 8 (0.29%) | ||
| Summary OR (95% CI) | 0.88 (0.32–2.43) | |||
| All-cause death | ||||
| Events, N (%) | 9 (2.3%) | 4 (1.0%) | 43 (1.6%) | 44 (1.8%) |
| Combined events, N (%) | Colchicine 52 (1.9%) | Placebo 48 (1.7%) | ||
| Summary OR (95% CI) | 1.24 (0.59–2.63) | |||
| Myocardial infarction | ||||
| Events, N (%) | 11 (2.8%) | 15 (3.8%) | 89 (3.8%) | 98 (4.1%) |
| Combined events, N (%) | Colchicine 100 (3.7%) | Placebo 125 (4.5%) | ||
| Summary OR (95% CI) | 0.89 (0.67–1.17) | |||
| Cerebrovascular accident | ||||
| Events, N (%) | 3 (0.8%) | 7 (1.8%) | 5 (0.2%) | 19 (0.8%) |
| Combined events, N (%) | Colchicine 8 (0.3%) | Placebo 26 (0.9%) | ||
| Summary OR (95% CI) | 0.31 (0.14–0.69) | |||
| Urgent revascularization | ||||
| Events, N (%) | 3 (0.8%) | 16 (4.0%) | 25 (0.9%) | 50 (1.8%) |
| Combined events, N (%) | Colchicine 28 (1.0%) | Placebo 66 (2.4%) | ||
| Summary OR (95% CI) | 0.36 (0.14–0.90) | |||
N number, OR odds ratio